Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  idarubicin hydrochloride
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine with or without Vorinostat in Treating Younger Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 60
Trial IDs: S1203, NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, NCT01802333
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Dasatinib, Cytarabine, and Idarubicin Hydrochloride in Treating Patients with High-Risk Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 12393, NCI-2013-01141, 106482, NCT01876953
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
Idarubicin, Cytarabine, and Pravastatin in Treating Patients with Poor-Risk Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S0919, NCI-2009-01183, CDR0000633749, SWOG-S0919, NCT00840177
Tretinoin and Arsenic Trioxide in Treating Patients with Newly Diagnosed Acute Promyelocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-040, NCI-2011-02334, NCT01404949
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARO-006, NCI-2015-00952, NCT02283177
Alisertib, Cytarabine, and Idarubicin in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-531, NCI-2013-01106, NCT01779843
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: HEMAML0030, NCI-2014-00169, NCT02049801
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0103, NCI-2014-01987, NCT02236013
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12D.588, NCI-2013-00632, 2012-55, NCT01822015
Start Over